0

Close
 
Upcoming Allied Market Research
2023
Thin Film Drugs Market

Thin Film Drugs Market

by Product (Oral Thin Film, Transdermal Thin Film, Others) and by Disease Indication (Schizophrenia, Migraine, Opioid Dependence, Nausea and Vomiting, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03780
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Thin Film Drugs Market

Request Now !

Thin film drugs have emerged as an alternative to tablets or capsules due to its effective therapeutic results. The drugs are made of polymers that rapidly dissolve when kept in the mouth or buccal cavity, delivering the drug directly to systemic circulation in the body.

The lower manufacturing costs of thin film drugs, increasing demand for effective drug delivery systems, coupled with increasing research to develop newer polymeric thin films are expected to increase the demand for thin film drugs. However, high costs associated with the treatment restrain the market growth. In addition, effective therapeutic output of the drugs when compared to traditional drugs provides a lucrative opportunity for the market to grow.

The global thin film drugs market is segmented based on product, disease indication, and region. On the basis of product, the market is divided into oral thin films, transdermal thin films, and others. Oral thin films are further bifurcated into sublingual film and fully dissolving dental/buccal films. Based on disease indication, it is categorized into schizophrenia, migraine, opioid dependence, nausea & vomiting, and others. By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Pfizer, Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc, Sumitomo Dainippon Pharma Co., Ltd., and IntelGenx Corp.

Key Benefit

  • The study provides an in-depth analysis of the global thin film drugs market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global thin film drugs market which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the global thin film drugs market has been provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global thin film drugs market.

 Thin Film Drugs Market Report Highlights

Aspects Details
By Product
  • Oral Thin Film
    • Sublingual Film
    • Fully Dissolving Dental or Buccal Film
  • Transdermal Thin Film
  • Others
By Disease Indication
  • Schizophrenia
  • Migraine
  • Opioid Dependence
  • Nausea and Vomiting
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Allergan plc,, Aquestive Therapeutics, Solvay, Sumitomo Dainippon Pharma Co., Ltd.,, Wolters Kluwer, Indivior PLC, ZIM Laboratories Limited, Novartis AG, IntelGenx Corp., Pfizer, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: THIN FILM DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Oral Thin Film

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Sublingual Film

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Fully Dissolving Dental or Buccal Film

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Transdermal Thin Film

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: THIN FILM DRUGS MARKET, BY DISEASE INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Indication

    • 5.2. Schizophrenia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Migraine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Opioid Dependence

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Nausea And Vomiting

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: THIN FILM DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Disease Indication

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Thin Film Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Disease Indication

      • 6.2.6. Canada Thin Film Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Disease Indication

      • 6.2.7. Mexico Thin Film Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Disease Indication

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Disease Indication

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Thin Film Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Disease Indication

      • 6.3.6. Germany Thin Film Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Disease Indication

      • 6.3.7. Italy Thin Film Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Disease Indication

      • 6.3.8. Spain Thin Film Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Disease Indication

      • 6.3.9. UK Thin Film Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Disease Indication

      • 6.3.10. Russia Thin Film Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Disease Indication

      • 6.3.11. Rest Of Europe Thin Film Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Disease Indication

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Disease Indication

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Thin Film Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Disease Indication

      • 6.4.6. Japan Thin Film Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Disease Indication

      • 6.4.7. India Thin Film Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Disease Indication

      • 6.4.8. South Korea Thin Film Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Disease Indication

      • 6.4.9. Australia Thin Film Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Disease Indication

      • 6.4.10. Thailand Thin Film Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Disease Indication

      • 6.4.11. Malaysia Thin Film Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Disease Indication

      • 6.4.12. Indonesia Thin Film Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Disease Indication

      • 6.4.13. Rest of Asia Pacific Thin Film Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Disease Indication

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Disease Indication

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Thin Film Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Disease Indication

      • 6.5.6. South Africa Thin Film Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Disease Indication

      • 6.5.7. Saudi Arabia Thin Film Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Disease Indication

      • 6.5.8. UAE Thin Film Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Disease Indication

      • 6.5.9. Argentina Thin Film Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Disease Indication

      • 6.5.10. Rest of LAMEA Thin Film Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Disease Indication

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Pfizer, Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novartis AG

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Wolters Kluwer

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Solvay

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Allergan Plc,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Sumitomo Dainippon Pharma Co., Ltd.,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. IntelGenx Corp.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. ZIM Laboratories Limited

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Aquestive Therapeutics

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Indivior PLC

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL THIN FILM DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL THIN FILM DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL THIN FILM DRUGS MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL THIN FILM DRUGS MARKET FOR MIGRAINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL THIN FILM DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL THIN FILM DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA THIN FILM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 15. U.S. THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. U.S. THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 17. CANADA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. CANADA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE THIN FILM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 28. ITALY THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. ITALY THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. UK THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. UK THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC THIN FILM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 41. CHINA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. CHINA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. INDIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. INDIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA THIN FILM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. UAE THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. UAE THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA THIN FILM DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA THIN FILM DRUGS, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 75. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 76. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 77. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 78. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. WOLTERS KLUWER: KEY EXECUTIVES
  • TABLE 85. WOLTERS KLUWER: COMPANY SNAPSHOT
  • TABLE 86. WOLTERS KLUWER: OPERATING SEGMENTS
  • TABLE 87. WOLTERS KLUWER: PRODUCT PORTFOLIO
  • TABLE 88. WOLTERS KLUWER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. SOLVAY: KEY EXECUTIVES
  • TABLE 90. SOLVAY: COMPANY SNAPSHOT
  • TABLE 91. SOLVAY: OPERATING SEGMENTS
  • TABLE 92. SOLVAY: PRODUCT PORTFOLIO
  • TABLE 93. SOLVAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. ALLERGAN PLC,: KEY EXECUTIVES
  • TABLE 95. ALLERGAN PLC,: COMPANY SNAPSHOT
  • TABLE 96. ALLERGAN PLC,: OPERATING SEGMENTS
  • TABLE 97. ALLERGAN PLC,: PRODUCT PORTFOLIO
  • TABLE 98. ALLERGAN PLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. SUMITOMO DAINIPPON PHARMA CO., LTD.,: KEY EXECUTIVES
  • TABLE 100. SUMITOMO DAINIPPON PHARMA CO., LTD.,: COMPANY SNAPSHOT
  • TABLE 101. SUMITOMO DAINIPPON PHARMA CO., LTD.,: OPERATING SEGMENTS
  • TABLE 102. SUMITOMO DAINIPPON PHARMA CO., LTD.,: PRODUCT PORTFOLIO
  • TABLE 103. SUMITOMO DAINIPPON PHARMA CO., LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. INTELGENX CORP.: KEY EXECUTIVES
  • TABLE 105. INTELGENX CORP.: COMPANY SNAPSHOT
  • TABLE 106. INTELGENX CORP.: OPERATING SEGMENTS
  • TABLE 107. INTELGENX CORP.: PRODUCT PORTFOLIO
  • TABLE 108. INTELGENX CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. ZIM LABORATORIES LIMITED: KEY EXECUTIVES
  • TABLE 110. ZIM LABORATORIES LIMITED: COMPANY SNAPSHOT
  • TABLE 111. ZIM LABORATORIES LIMITED: OPERATING SEGMENTS
  • TABLE 112. ZIM LABORATORIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 113. ZIM LABORATORIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. AQUESTIVE THERAPEUTICS: KEY EXECUTIVES
  • TABLE 115. AQUESTIVE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 116. AQUESTIVE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 117. AQUESTIVE THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 118. AQUESTIVE THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. INDIVIOR PLC: KEY EXECUTIVES
  • TABLE 120. INDIVIOR PLC: COMPANY SNAPSHOT
  • TABLE 121. INDIVIOR PLC: OPERATING SEGMENTS
  • TABLE 122. INDIVIOR PLC: PRODUCT PORTFOLIO
  • TABLE 123. INDIVIOR PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL THIN FILM DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL THIN FILM DRUGS MARKET
  • FIGURE 3. SEGMENTATION THIN FILM DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN THIN FILM DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHIN FILM DRUGS MARKET
  • FIGURE 11. THIN FILM DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. THIN FILM DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. THIN FILM DRUGS MARKET SEGMENTATION, BY BY DISEASE INDICATION
  • FIGURE 16. THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. THIN FILM DRUGS MARKET FOR MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. THIN FILM DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: THIN FILM DRUGS MARKET
  • FIGURE 27. Top player positioning, 2022
  • FIGURE 28. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. WOLTERS KLUWER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. WOLTERS KLUWER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. WOLTERS KLUWER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. SOLVAY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. SOLVAY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. SOLVAY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. ALLERGAN PLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. ALLERGAN PLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. ALLERGAN PLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. SUMITOMO DAINIPPON PHARMA CO., LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. SUMITOMO DAINIPPON PHARMA CO., LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. SUMITOMO DAINIPPON PHARMA CO., LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. INTELGENX CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. INTELGENX CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. INTELGENX CORP.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. ZIM LABORATORIES LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. ZIM LABORATORIES LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. ZIM LABORATORIES LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. AQUESTIVE THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. AQUESTIVE THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. AQUESTIVE THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. INDIVIOR PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. INDIVIOR PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. INDIVIOR PLC: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Thin Film Drugs Market

Start reading.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers